Pharmacologic Management Options for Patients With Tardive Dyskinesia

In this podcast episode, Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, provide a wealth of information on VMAT2 inhibitors and their use for tardive dyskinesia (TD) management. Their discussion includes information on VMAT2 inhibitor emergence in clinical practice, mechanism of action, adverse event profiles, insurance coverage, and strategies for initiation and titration. In addition to VMAT2 inhibitors, the experts touch on off-label options for TD management and their place in the TD management paradigm.

Presenters:

Diana O. Perkins, MD, MPH
Professor, Psychiatry
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Rajiv Tandon, MD
Emeritus Professor of Psychiatry
Department of Psychiatry
Western Michigan University Homer Stryker MD College of Medicine
Kalamazoo, Michigan

This content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences.

For more programs in this series, visit:
https://bit.ly/3yOL8f7